Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
701-720 of 998 trials

Hepatoblastoma and Hepatocarcinoma: Personalized Treatment Study

We are investigating new ways to tailor treatments for children with liver cancer to improve effectiveness and reduce side effects. This study also aims to better understand the genetic features of these tumors.

Hepatoblastoma and Liver CancerConfirmation phase (III)No PlaceboInvestigational MedicinesPartially RemoteOncologyPediatrics

Arrhythmogenic Cardiomyopathy: Atorvastatin Study

We are evaluating whether atorvastatin can help slow down heart function decline in people with Arrhythmogenic Cardiomyopathy. The study also looks at its safety and effects on heart-related markers.

Arrhythmogenic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Dazukibart for Idiopathic Inflammatory Myopathies

We are studying the long-term safety and effectiveness of dazukibart in people with dermatomyositis or polymyositis who have completed prior treatment. This research aims to understand how well the medication works in reducing symptoms and improving health.

Idiopathic Inflammatory Myopathy1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Vaborem® for Serious Infections in Children

We are studying how Vaborem® is processed in the body and its safety in children with suspected or confirmed Gram-negative infections. This trial includes kids from birth to under 18 years old.

Acute Pyelonephritis≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteInfectious DiseasesPediatrics

Alzheimer's Dementia: ITI-1284 for Agitation

We are studying whether ITI-1284 can help reduce agitation in patients with Alzheimer's dementia compared to a placebo. The trial will also assess the safety and tolerability of this new treatment.

Alzheimer's Disease3-6 monthsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

Rett Syndrome: Leriglitazone Study for Children

We are testing the safety and effects of a new medication, leriglitazone, in children with Rett Syndrome. The study aims to understand its impact on development and caregiver challenges.

Rett Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurologyPediatrics

NPM1-Mutated Acute Myeloid Leukemia: Eltanexor Study

We are evaluating a new drug called eltanexor for patients with relapsed or refractory NPM1-mutated acute myeloid leukemia. The study aims to see if it is safe and effective in treating this condition.

Acute Myeloid LeukemiaEfficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Antibiotic Treatment for Critically Ill Patients

We are studying whether a short course of high-dose antibiotics is as effective as standard treatment for critically ill patients with pneumonia, intra-abdominal infections, or bloodstream infections. This research may help reduce antibiotic use while maintaining patient safety.

Pneumonia and Bacterial Infections>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Inflammatory Bowel Disease: Vedolizumab Dose Reduction Study

We are studying whether patients with inflammatory bowel disease can safely lower their dose of vedolizumab. This trial will help us understand the effects on health, costs, and quality of life.

Inflammatory Bowel Disease1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Chronic Spontaneous Urticaria: BP11 vs. Xolair

We are comparing a new treatment, BP11, to Xolair for patients with chronic spontaneous urticaria who haven't responded to antihistamines. The goal is to see if BP11 is as effective and safe as Xolair.

Chronic Spontaneous Urticaria6-12 monthsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Colorectal Cancer Prevention: Mesalamine for Lynch Syndrome

We are studying whether mesalamine can help prevent colorectal cancer in patients with Lynch syndrome. This trial compares mesalamine to a placebo to see if it reduces the occurrence of tumors.

Lynch Syndrome>2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesPartially RemoteGastroenterologyOncology

Post-Surgery Pain Management: Ropivacaine Concentration Study

We are investigating whether different concentrations of ropivacaine can help reduce pain after volar plate surgery. This study aims to see if higher doses lead to less rebound pain and better overall pain control.

Radius Fracture>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteOrthopedics and TraumatologyOtolaryngologyPsychiatry

Severe Asthma: Predicting Response to Benralizumab

We are studying whether early blood tests can predict how well severe asthma patients respond to Benralizumab treatment. This may help identify those who are likely to experience fewer asthma attacks.

Severe Asthma>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteAllergologyPulmonology

CRN04894 for Hormonal Imbalance

We are studying the safety and effectiveness of CRN04894 in participants with hormonal imbalances. The goal is to see how it affects hormone levels and overall health.

Congenital Adrenal HyperplasiaEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Short Course Antibiotics for Gram-Negative Bacteremia

We are studying whether a 5-day antibiotic treatment is as effective and safe as longer treatments for hospitalized adults with Gram-negative bacteremia from urinary tract infections.

Gram-negative Bacteremia3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Type 1 Diabetes: Semaglutide Treatment Study

We are investigating whether adding semaglutide to standard treatment helps people with type 1 diabetes and 'double diabetes' better control their blood sugar and weight. This study will also look at insulin use and potential side effects.

Double Diabetes6-12 monthsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteDiabetologyEndocrinology

Preventing Pancreatic Fistulas: Botulinum Toxin Injection Study

We are studying whether botulinum toxin injections can help prevent complications after pancreatic surgery in patients undergoing distal pancreatectomy. This trial aims to improve recovery and reduce the risk of serious postoperative issues.

Pancreatic Fistula≤3 monthsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteGastroenterologyInternal Medicine

Gastrointestinal Stromal Tumors: IDRX-42 Treatment Study

We are testing a new treatment called IDRX-42 for individuals with advanced gastrointestinal stromal tumors that cannot be surgically removed. The study aims to find a safe dosage and assess how well it works against the cancer.

Gastrointestinal Stromal Tumor (GIST)1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyOncology

Sepsis-Induced Hypotension: REGN7544 Treatment Study

We are studying REGN7544 to see if it can help adults with sepsis-induced hypotension manage their blood pressure and reduce the need for other medications. The trial will also assess the safety and effects of this treatment.

Sepsis-Induced Hypotension3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInfectious Diseases

Lung Cancer: BMS-986507 Treatment Study

We are testing a new treatment called BMS-986507 for adults with advanced lung cancer to see if it is safe and to find the best dose when used with other therapies.

Malignant Solid TumorSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology